April 26, 2025 06:00 AM EDT

Earnings season is upon us; Makary on rare disease; Startup is first to inject CRISPR in the brain; and more

Nicole DeFeudis

Editor

Max Gelman

Senior Editor

Welcome back to Endpoints Weekly! Our team of reporters covered first-quarter earnings results from a handful of companies this week. See below for pharma executives� …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Earnings season is upon us; Makary on rare disease; Startup is first to inject CRISPR in the brain; and more

Nicole DeFeudis

Editor

Max Gelman

Senior Editor

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

New fund will pressure flailing biotechs, as investor frustration boils over

Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient

Vaccine biotechs say they’ve been told to stop next-gen Covid work under a Biden-era project

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Earn­ings sea­son is up­on us; Makary on rare dis­ease; Start­up is first to in­ject CRISPR in the brain; and more

Editor

Senior Editor

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

Earnings season is upon us; Makary on rare disease; Startup is first to inject CRISPR in the brain; and more